Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1141 to 1155 of 2042 results for guidelines

  1. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

  2. Galcanezumab for preventing migraine (TA659)

    Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.

  3. Thermogard XP for therapeutic hypothermia after cardiac arrest (MIB37)

    NICE has developed a medtech innovation briefing (MIB) on Thermogard XP for therapeutic hypothermia after cardiac arrest

  4. Workplace health - older employees

    Discontinued [GID-PHG59]

  5. Temperature control to improve neurological outcomes after cardiac arrest (IPG782)

    Evidence-based recommendations on temperature control to improve neurological outcomes after cardiac arrest. This involves controlling a person’s body temperature while they are still unconscious after their heart has been restarted. Either their body is kept at a normal temperature of between 36.5°C and 37.5°C to prevent fever, or it is cooled to between 32.0°C and 36.0°C (therapeutic hypothermia).

  6. Common mental health problems: identification and pathways to care (CG123)

    We withdrew this guideline in May 2024, because all of the recommendations are now covered in other NICE guidelines, or are out of date and no longer relevant to clinical practice. For guidance on common mental health problems, see our guidelines on:

  7. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

    Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.

  8. The OPTIMIZER smart system for managing heart failure (MIB186)

    NICE has developed a medtech innovation briefing (MIB) on the OPTIMIZER smart system for managing heart failure .

  9. Balloon cryoablation for squamous dysplasia of the oesophagus (IPG683)

    Evidence-based recommendations on balloon cryoablation for squamous dysplasia of the oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells.

  10. Percutaneous electrical nerve stimulation for refractory neuropathic pain (IPG450)

    Evidence-based recommendations on percutaneous electrical nerve stimulation for refractory neuropathic pain. This involves inserting electrode needles underneath the skin connected to a stimulator device.

  11. Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

    Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

  12. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MIB174)

    NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .

  13. RT300 for spinal cord injury rehabilitation (MIB169)

    NICE has developed a medtech innovation briefing (MIB) on RT300 for spinal cord injury rehabilitation .

  14. Healthy start vitamins: special report on cost effectiveness (ECD5)

    Healthy start vitamins: special report on cost effectiveness

  15. IQoro for hiatus hernia (MIB176)

    NICE has developed a medtech innovation briefing (MIB) on IQoro for hiatus hernia .